Neuren Pharmaceuticals Limited announced the cessation of Dr. John Douglas Wilson as director, effective May 20, 2013.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
19.47 AUD | +0.41% | -10.03% | -22.03% |
28/05 | Transcript : Neuren Pharmaceuticals Limited - Shareholder/Analyst Call | |
27/05 | Neuren Phase 2 Trial Shows Significant Improvements in Pitt Hopkins Syndrome | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.03% | 163.68Cr | |
+45.82% | 77TCr | |
+40.95% | 63TCr | |
-6.16% | 35TCr | |
+19.86% | 33TCr | |
+9.32% | 30TCr | |
+18.45% | 25TCr | |
+11.88% | 22TCr | |
-0.78% | 22TCr | |
+5.90% | 16TCr |
- Stock Market
- Equities
- NEU Stock
- News Neuren Pharmaceuticals Limited
- Neuren Pharmaceuticals Limited Announces the Cessation of John Douglas Wilson as Director